XML 60 R46.htm IDEA: XBRL DOCUMENT
v3.23.2

Restructuring - Additional Information (Detail) $ in Thousands |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | --- | ---
Jun. 05, 2023 USD ($) | Mar. 08, 2023 USD ($) | Jan. 12, 2023 USD ($) | Jun. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Feb. 28, 2023 USD ($) | May 31, 2022 USD ($) | Mar. 31, 2022 Employee | Nov. 30, 2021 | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($)
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of employees terminated |  |  |  |  |  |  |  |  | 35.00% |  |  |  |
Number of Employees terminated | Employee |  |  |  |  |  |  |  | 22 |  |  |  |  |
Remaining number of full time employees | Employee |  |  |  |  |  |  |  | 5 |  |  |  |  |
Proceeds from Sale of Intangible Assets |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |
Gain (loss) on disposal |  |  |  |  |  |  |  |  |  | $ 57,245 |  | 4,736 | $ 57,245
Amount of dividend payment |  |  | $ 7,600 |  |  |  |  |  |  |  |  |  |
Contingent Value Rights Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Distribution to CVR holders from asset sale proceeds | $ 3,500 | $ 200 |  |  | $ 200 |  |  |  |  |  |  |  |
Amount of dividend payment | $ 3,500 | $ 200 |  | $ 3,500 |  |  |  |  |  |  |  |  |
Vertex Pharmaceuticals Incorporated |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sale of Intangible Assets |  |  |  |  |  |  | $ 60,000 |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | 55,000 |  |  |  |  |  |
Post closing indemnification obligation |  |  |  |  |  |  | 5,000 |  |  |  |  |  |
Gain (loss) on disposal |  |  |  |  |  |  | $ 57,400 |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  | 2,600 |  |  |
GCBP Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sale of Intangible Assets |  |  |  |  |  | $ 6,000 |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | 1,000 |  |  |  |  |  |  |
Post closing indemnification obligation |  |  |  |  |  | 5,000 |  |  |  |  |  |  |
Gain (loss) on disposal |  |  |  |  |  | $ 4,700 |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  |  | $ 800 |
Dren Bio, Inc. and Copia Scientific, LLC |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total consideration for sales agreements |  |  |  |  |  |  |  |  |  | 400 |  |  | 400
Gain (loss) on disposal |  |  |  |  |  |  |  |  |  | $ (200) |  |  | $ (200)
Operating Expense |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring Cost And Reserve [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Restructuring costs |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  |

X
- Definition Disposal of assets transaction costs. + References No definition available. + Details
Name: | cbio_DisposalOfAssetsTransactionCosts
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Distribution from asset sale proceeds. + References No definition available. + Details
Name: | cbio_DistributionFromAssetSaleProceeds
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Post closing indemnification obligation. + References No definition available. + Details
Name: | cbio_PostClosingIndemnificationObligation
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remaining number of full time employees. + References No definition available. + Details
Name: | cbio_RemainingNumberOfFullTimeEmployees
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Severance and other costs. + References No definition available. + Details
Name: | cbio_SeveranceAndOtherCosts
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | cbio_UpfrontPaymentReceived
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfDividendsCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of positions eliminated during the period as a result of restructuring activities. + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_RestructuringCostAndReserveLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=cbio_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cbio_VertexPharmaceuticalsIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cbio_GCBiophrarmaCorpAssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cbio_DrenBioIncAndCopiaScientificLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |